Analysts: JPMorgan Could Reverse Underperformance and 3 Other Research Notes to Check Out
JPMorgan (NYSE:JPM): Wells Fargo believes that JPMorgan is making progress on reducing headline risks after it announced a $920 milion settlement. Wells thinks that shares can reverse their recent underperformance if JPMorgan can successfully resolve its regulatory risk in a timely manner. The firm keeps an Outperform rating on the stock.
Green Mountain Coffee Roasters (NASDAQ:GMCR): Dougherty said IRI K-Cup data for the 4 week period ended September 8 was 20.2 percent, down from the 24.7 percent growth rate for the 4 week period ended August 11. Realized pricing was down 140 basis points year over year for the period ending September 8, improving from down 240 percent for the 4 week period ending August 11.
The Walt Disney Company (NYSE:DIS): Morgan Stanley downgraded Disney to Equal Weight from Overweight. The analyst lowered estimates below consensus and said visibility is more difficult, as its previous thesis of ESPN pricing power and returns on Parks investments is largely played out. The firm expects growth to come from creative success and acquisitions and sees stronger growth opportunities elsewhere. The shares’ price target has been lowered to $70.
Jazz Pharmaceuticals (NASDAQ:JAZZ): Cowen believes Jazz Pharmaceuticals still has considerable upside despite its year to date performance and recommends aggressively adding to current positions. The firm has increased confidence in the company’s ability to create even more value from their current commercial assets. Shares are Outperform rated with a $120 price target.
Don’t Miss: 7 Companies That Break the Advertising Bank.